During the past decade, hôpital Emile Muller conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 10 clinical trials were completed, i.e. on average, 27.8% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 5 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "hôpital Emile Muller" #1 sponsor was "Intergroupe Francophone du Myelome" with 5 trials, followed by "Celgene" with 3 trials sponsored, "French Innovative Leukemia Organisation" with 3 trials sponsored, "Groupe Hospitalier de la Region de Mulhouse et Sud Alsace" with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 38 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "hôpital Emile Muller" #1 collaborator was "Amgen" with 3 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 2 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "Intergroupe Francophone du Myelome" with 2 trials as a collaborator and "Ministry of Health, France" with 2 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "hôpital Emile Muller" are "Multiple Myeloma" (10 trials), "Diffuse Large B-cell Lymphoma" (3 trials), "COVID" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials) and "Follicular Lymphoma" (2 trials). Many other conditions were trialed in "hôpital Emile Muller" in a lesser frequency.

Most popular intervention types in "hôpital Emile Muller" are "Drug" (34 trials), "Procedure" (8 trials), "Device" (7 trials), "Other" (7 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (3 trials), "Atezolizumab" (2 trials), "Carboplatin" (2 trials), "Carfilzomib" (2 trials) and "Daratumumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "hôpital Emile Muller" are 58 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 21 active trials in "hôpital Emile Muller". 1 are not yet recruiting, 9 are recruiting, 10 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 28 completed trials in hôpital Emile Muller, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in hôpital Emile Muller, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 11 trials that are defined as “Not Applicable".